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Background: Monitoring drug resistance in Mycobacterium tuberculosis is essential to curb the spread of
tuberculosis (TB). Unfortunately, drug susceptibility testing is currently not available in Papua New Guinea (PNG) and
that impairs TB control in this country. We report for the first time M. tuberculosis mutations associated with
resistance to first and second-line anti-TB drugs in Madang, PNG. A molecular cluster analysis was performed to
identify M. tuberculosis transmission in that region.
Results: Phenotypic drug susceptibility tests showed 15.7% resistance to at least one drug and 5.2% multidrug
resistant (MDR) TB. Rifampicin resistant strains had the rpoB mutations D516F, D516Y or S531L; Isoniazid resistant
strains had the mutations katG S315T or inhA promoter C15T; Streptomycin resistant strains had the mutations rpsL
K43R, K88Q, K88R), rrs A514C or gidB V77G. The molecular cluster analysis indicated evidence for transmission of
resistant strain.
Conclusions: We observed a substantial rate of MDR-TB in the Madang area of PNG associated with mutations in
specific genes. A close monitoring of drug resistance is therefore urgently required, particularly in the presence of
drug-resistant M. tuberculosis transmission. In the absence of phenotypic drug susceptibility testing in PNG,
molecular assays for drug resistance monitoring would be of advantage.
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Mycobacterium tuberculosis drug resistance is a global
concern. In Papua New Guinea (PNG), the estimated tu-
berculosis (TB) incidence rate is 303/100000 population,
with 5% multidrug resistant TB (MDR-TB) among new
cases [1]. Culture-based drug susceptibility testing (DST)
requires infrastructures often too sophisticated for
resource-constrained settings. Detecting resistance-
associated mutations is a faster alternative, as shown by
Genotype MTBDRplus (Hain Life science) [2] or Xpert
MTB/RIF (Cepheid) [3]. To monitor drug resistance mo-
lecularly, the distribution of drug resistance-conferring* Correspondence: Hans-Peter.Beck@unibas.ch
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reproduction in any medium, provided the ormutations in a given setting needs to be known, and
such data is currently missing for PNG. We report
mutations associated with drug resistance among TB
isolates in the Madang area of PNG and provide evi-
dence for transmission of drug-resistant M. tuberculosis.Results and discussion
The patient characteristics and detailed M. tuberculosis
genotypes were reported elsewhere [4]. In brief, 60
patients were recruited in the frame of a pilot study in
2005-2007 and 201 in the frame of a treatment cohort
study in 2009-2010. History of previous TB treatment
was reported in 16.9% (31/201) of the 2009-2010
patients, for whom data was collected. Molecular ana-
lyses were performed on the DNA from 173 successfully
grown isolates and phenotypic DST was obtained for
172 isolates. From the six previously described M.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Euro-American (Lineage 4), 39/173 (22.5%) East-Asian
(Lineage 2, includes Beijing genotype), and 1/173 (0.6%)
Indo-Oceanic (Lineage 1).
Overall, 27/172 (15.7%) isolates were resistant to ≥1
drug: 15/172 (8.7%) monoresistant, 3/172 (1.8%) polyre-
sistant and 9/172 (5.2%) MDR. A total of 10/172 (5.8%)
strains were Rifampicin (RIF) resistant, 21/172 (12.2%)
Isoniazid (INH) resistant (13 low-level [0.1 mg/L], 8
high-level [0.4 mg/L]), 9/172 (5.2%) Streptomycin (STR)
resistant, and 4/172 (2.3%) Ethionamide (ETH) resistant.
Among resistant isolates, the genes harboring drug re-
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Figure 1 List of all mutations observed in each of the 27 strains resis
positions, except for rrs gene. RIF: Rifampin; INH: Isoniazid; STR: Streptomyci
Multidrug resistant.observed mutations in katG, inhA promoter, ahpC pro-
moter, rpoB, embB, pncA, rpsL, rrs, gidB, and gyrA are
listed in Figure 1.
INH resistant isolates harbored mutations in katG
(codon S315T) or inhA promoter (nucleotide C15T). All
isolates with katG S315T were resistant to 0.4 mg/L
INH except one, which was sensitive to this concentra-
tion of INH. On the other hand, all isolates with inhA
promoter mutation were sensitive at this drug concen-
tration (but resistant at 0.1 mg/L), thus confirming the
association between inhA promoter mutations and low-
level INH resistance [6]. Among all 6/9 MDR-TB isolates
with either katG or inhA promoter mutations, all hadrp
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tant to at least one drug. The polymorphisms are indicated at codon
n; PZA: Pyrazinamide; ETH: Ethionamide; PAS: p-aminosalicylic acid; MDR:
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moter mutation. This only MDR-TB case with an inhA
promoter mutation belonged to the four MDR-TB cases,
which were additionally ETH resistant. Mutations in
inhA promoter have been shown to cause INH and ETH
cross-resistance and were thereby associated with higher
risks of extensively drug resistant TB [7].
Eight INH resistant strains (38.1%) had no katG or
inhA promoter mutation. Only 850 bp of katG were
sequenced and mutations may therefore have been
missed. However, katG mutations outside this region are
rarer [6,8,9]. Alternatively, these strains might harbor
mutation(s) in the >20 other genes reported as poten-
tially associated with INH resistance (genes iniA or x for
example) [8].
We did not observe any ahpC promoter mutation,
thought to compensate the reduced catalase-peroxidase
activity resulting from katG mutations [10,11]. Because
the INH resistance-conferring mutations observed here,
i.e. katG S315T and inhA promoter C15T, are known to
be associated with a low fitness cost [11], they might not
require compensation.
All RIF resistant isolates harbored mutations in rpoB
at codons D516F, D516Y or S531L except one, which
did not have any mutation in the 600pb rpoB fragment
sequenced. DST was repeated for this case, confirming
the MDR phenotype. Furthermore, common rpoB, katG
and inhA promoter mutations were excluded by Geno-
type MTBDRplus. Nevertheless, it has been estimated
that mutations in the RIF resistance determining region
(81-bp region in rpoB) account only for 95% of RIF re-
sistance [6] and therefore other mechanisms cannot be
excluded. Mutation S531L has been linked to high-level
RIF resistance [12], whereas D516Y was associated with
low-level resistance [13-15]. Mutation D516F has only
been reported in Kazakhstan [16] and may also cause
low-level resistance. Low-level RIF resistance has been
little considered, but could influence treatment, espe-
cially knowing that phenotypic DST outcomes may differ
from the actual efficacy of the anti-TB drugs in patients
[17].
STR resistant isolates harbored mutations in rpsL
(codons K43R, K88Q, K88R) and rrs (nucleotide
A514C), as previously reported [18,19]. One isolate was
mutated at codon V77G in gidB, a mutation which was
not reported before. One STR resistant isolate did not
present any mutation in any of these genes.
Mutations in gidB have been associated with low-level
STR resistance [20,21], but were also reported in sensi-
tive strains [22]. In this study, gidB mutations A10P,
L16R, E92D, and A205A were observed among strains
resistant to other drugs than STR. We further explored
gidB mutations in whole genomes of 21 pan-susceptible
strains representative of the six defined M. tuberculosislineages [23]. Mutation gidB V77G, which we observed
in one STR resistant isolate from PNG, could not be
found in any of the 21 pan-susceptible strains. This mu-
tation could therefore indeed be involved in drug resist-
ance or could be a transitory polymorphism in the
population. The mutation A10P observed in one STR
sensitive isolate was not found in any of the 21 pan-
susceptible genomes. Mutations L16R was observed in
genome sequences from Lineage 4 strains (Euro-Ameri-
can lineage) and E92D in Lineage 2 strains (East-Asian
lineage). This supports the recent observation that gidB
L16R occurred in LAM strains (i.e. Lineage 4), whereas
gidB E92D occurred in Beijing strains [24]. A205A
appeared mutated in all strains not belonging to Lineage
4, therefore indicating that this mutation, identified by
comparison to H37Rv, is a Lineage 4 mutation. Observa-
tions from the 21 pan-susceptible genomes suggest that
most gidB mutations rather reflect M. tuberculosis
lineage evolution than drug resistance.
Clusters were defined for strains sharing identical spo-
ligotype and 24 locus mycobacterial interspersed repeti-
tive unit variable number of tandem repeats (MIRU-
VNTR) patterns. Among isolates with complete patterns,
72/162 (44.4%) were clustered. Despite potential fitness
costs associated with resistance-conferring mutations
[25], the proportion of clustered strains was not signifi-
cantly different among drug-sensitive (60/137, 43.8%)
and drug-resistant (12/25, 48.0%) isolates of M.
tuberculosis.
To distinguish between primary resistance and
acquired resistance, clustered isolates sharing identical
drug resistance-conferring mutations were considered.
Five of the 12 (41.7%) drug-resistant isolates involved in
molecular clusters shared their drug resistance-
conferring mutations with other isolates in the same
cluster, thus strongly suggesting patient-to-patient
transmission.Conclusions
This study provides so far missing data about drug
resistance-conferring mutations in M. tuberculosis iso-
lates from Madang in PNG. Monitoring drug resistance
is essential to prevent the spread of resistant bacteria, es-
pecially in diseases requiring lengthy treatments such as
TB. Our data suggests that not all present drug resist-
ance associated mutations may be detected by molecular
tests, which mainly focus on a subset of polymorphisms
only. However, given the complex implementation of
culture-based DST in resource-constrained settings,
PNG may be well suited for an accelerated roll-out of
molecular drug resistance testing in order to better
tackle the emergence and the transmission of drug-
resistant M. tuberculosis strains.
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Study site and patient characteristics
In 2005-2007, a pilot study was conducted in Madang
(PNG) at the Modillion Hospital, which is the main
point of care in Madang province. In April 2009, a co-
hort study was initiated in the same hospital and two
smaller health centers in close vicinity to Madang town.
Patients above 14 years were included if having micro-
scopically confirmed pulmonary TB or other clinical evi-
dence suggesting smear-negative TB. Treatment and
follow-up were planed according to the directly observed
treatment, short-course (DOTS) program. Demographic
and clinical data were available for all patients, except
those recruited during the 2005-2007 pilot study.
Sample processing
Sputum samples were examined by light microscopy
after Ziehl-Neelsen staining. Decontamination was con-
ducted according to Petroff ’s method [26]. DST was per-
formed by proportion method [27] at the Queensland
Mycobacterial Reference Laboratory in Australia using
BACTEC™ MGIT™ 960 (Beckton Dickinson, USA) and
the following drug concentrations: RIF (1.0 μg/mL), INH
(0.1 and 0.4 μg/mL), Ethambutol (5.0 μg/mL), Pyrazina-
mide (100 μg/mL), Streptomycin (1.0 μg/mL), Amikacin
(1.0 μg/mL), Kanamycin (5.0 μg/mL), Ofloxacin (2.0 μg/
mL), Capreomycin (2.5 μg/mL), ETH (5.0 μg/mL), p-
Aminosalicylic acid (4.0 μg/mL), and Cycloserine
(50.0 μg/mL). Isolates resistant to one drug were cate-
gorized as monoresistant, isolates resistant to at least
INH and RIF were categorized as MDR and isolates re-
sistant to at least one drug but not MDR were consid-
ered polyresistant. DNA was extracted from cultures
using Instigate Matrix (Bio-Rad, USA) and sent to the
Swiss Tropical and Public Health Institute for molecular
analyses.
Strain genotyping
Spoligotyping and 24 locus MIRU-VNTR were used to
define strain clusters as previously described [28,29].
The online MIRU-VNTRplus platform was used for
cluster identification (www.miru-vntrplus.org [30]).
Clusters were defined for strains sharing identical spoli-
gotype and 24 locus MIRU-VNTR patterns. Strains were
assigned to one of the six previously described lineages
by real-time PCR identification of specific single nucleo-
tide polymorphisms (SNPs) [5,31-33].
Drug resistance mutations
The following genes (or gene regions) were sequenced
to capture drug resistance conferring SNPs: rpoB, katG,
inhA promoter, ahpC promoter, embB, pncA, rpsL, rrs,
gidB, and gyrA (see Additional file 1: Table S1 for pri-
mers and PCR conditions). Sequencing was performedby Macrogen (The Netherlands). Observed mutations
were compared to the online Tuberculosis Drug Resist-
ance Mutation Database (TBDream, www.tbdreamdb.
com [8]).
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